transformative Therapeutics

Therapeutics

overview

A pipeline of transformative antibody therapies

We develop next-generation antibody therapeutics for patients, with a current focus on oncology, inflammatory disease, and immunology.

We start with disease biology, identifying therapeutic opportunities where advanced molecular engineering will deliver a transformative therapy for patients. We then use frontier AI to iteratively build best-in-class medicines uniquely enabled by BigHat's platform, simultaneously optimizing antibody sequence, geometry, and function. This discipline defines every program in our pipeline.

Pipeline

Advancing a pipeline of wholly-owned and partnered antibody therapeutics from discovery through clinical development.
Target(s)
Therapeutic area
Program
Modality
Stage of development
Program
BHB810
Therapeutic area
Gastric & GEJ Adenocarcinoma
Target(s)
CDH17
Modality
ADC
Stage of development
Discovery
Optimization
IND-enabling
Phase 1
Program
BHB299
Therapeutic area
Solid Tumors
Target(s)
CEACAM6xCD3
Modality
TCE
Stage of development
Discovery
Optimization
IND-enabling
Phase 1
Program
BHB-AV
Therapeutic area
I&I
Target(s)
Undisclosed
Modality
TCE
Stage of development
Discovery
Optimization
IND-enabling
Phase 1
Program
BHB-VH
Therapeutic area
Oncology
Target(s)
Undisclosed
Modality
TCE-plus
Stage of development
Discovery
Optimization
IND-enabling
Phase 1
Program
Partner programs
Therapeutic area
Multiple
Target(s)
Multiple targets
Modality
Multiple
Stage of development
Discovery
Optimization
IND-enabling
Phase 1
Current / completed stage Upcoming stage
Capabilities

Therapeutic Capabilities

We can create drugs today that are inaccessible with only traditional technologies.

MPO

Affinity, stability, expression and function are optimized together in every design round, not one at a time.

Internalization

Binders tuned for rapid uptake and release into target cells, maximizing payload delivery into each cell.

Multispecifics

VHH, scFv, and Fab building blocks are optimized and assembled into multispecific formats that reliably express well and behave as designed.

Paralogue Specificity

Antibodies that bind the intended target and leave its closely related family members untouched.

pH Conditionality

Binding that depends on environmental pH, unlocking tissue specificity and endolysosomal release.

AND/NOT Logic

Multispecifics that act only where two targets are present (A+B), or are blocked where a healthy-associated antigen appears (A NOT A+B).

IF-BETTER Logic

Low-affinity, high-avidity designs that engage cells overexpressing the target and spare cells with lower levels.

Developability & Cross-Reactivity

Candidates built from the start for manufacturability, stability and equivalent binding to human and primate targets.

PARTNER

Partner with us

BigHat engages with strategic partners to tackle complex protein therapeutic design challenges.